N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Phase 2 N=26 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Phase 2 N=226 Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.9; 10.7 months — p=0.5157
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 3 N=1,047 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
Lung Cancer
Primary: Overall Survival in Lymph Nodes Examined Patients — NA; NA years — p=0.007
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Phase 2 N=44 Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer · Brain Cancer
Primary: Median Survival — 11.8 months
Phase 2 N=25 Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Phase 2 N=13 Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases
Non-small Cell Lung Cancer
Primary: Intracranial Objective Response Rate — 6; 0; 5; 0 Participants
Phase 2 N=170 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
Adenosquamous Lung Carcinoma · Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma
Primary: Percentage of Participants Alive Without Progression (Progression-free Survival) — 60.4; 51.3 percentage of participants — p=0.7563
Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Phase 3 N=437 A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
N/A N=4 Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Phase 2 N=52 Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Time to Progression — 3.12; 1.64 months
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
N/A N=30 DBT for Metastatic Lung Cancer
Lung Cancer Metastatic
Primary: Feasibility as Measured by Study Accrual — 31 Participants
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=101 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants
N/A N=5,279 A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
Non-Small Cell Lung Cancer
Primary: Duration of Treatment of Anti-cancer Drugs — 11; 14; 9.4; 15.8 Months
Phase 2 N=24 Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung Cancer
Primary: 6 Month Progression-Free Survival — 69 percentage of participants
Phase 2 N=71 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Phase 2 N=3 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 2 N=39 Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)
Primary: Therapeutic Efficacy of Anti-CTLA-4 mAb and Concurrent Local RT in NSCLC Patients With Metastatic Disease. — 7 Participants
Phase 2 N=37 Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Objective Response Rate — 10.8 percentage of participants